Paxlovid Európai Unió - lengyel - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Comirnaty Európai Unió - lengyel - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - szczepionki - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.

Zulvac 1 Ovis Európai Unió - lengyel - EMA (European Medicines Agency)

zulvac 1 ovis

zoetis belgium sa - inaktywowany wirus choroby niebieskiego języka, serotyp-1 - immunologiczne - owca - aktywna immunizacja owiec od 1. 5 miesięcy w zapobieganiu wiremii wywołanej przez wirus choroby niebieskiego języka, serotypy-1. początek odporności: 21 dni po zakończeniu pierwotnego schematu szczepień. czas trwania odporności: 12 miesięcy.

Zulvac 8 Ovis Európai Unió - lengyel - EMA (European Medicines Agency)

zulvac 8 ovis

zoetis belgium sa - inaktywowany wirus choroby niebieskiego języka, serotyp 8, szczep btv-8 / bel2006 / 02 - immunologiczne - owca - aktywna immunizacja owiec od 1. 5 miesięcy w zapobieganiu wiremii wywołanej przez wirus choroby niebieskiego języka, serotyp 8.

Zulvac 1 Bovis Európai Unió - lengyel - EMA (European Medicines Agency)

zulvac 1 bovis

zoetis belgium sa - inaktywowany wirus choroby niebieskiego języka, serotyp 1 - immunologiczne - bydło - aktywna immunizacja bydła w wieku od 2,5 miesiąca w zapobieganiu wiremii wywołanej przez wirus choroby niebieskiego języka, serotyp 1. początek odporności: 15 dni po zakończeniu pierwszego szczepienia. czas trwania odporności: 12 miesięcy.

Zulvac 8 Bovis Európai Unió - lengyel - EMA (European Medicines Agency)

zulvac 8 bovis

zoetis belgium - inaktywowany wirus choroby niebieskiego języka, serotyp 8, szczep btv-8 / bel2006 / 02 - immunologiczne - bydło - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.